From the Guidelines
Prila 5% cream should not be used in children as there is no available evidence to support its safety and efficacy in this population. The provided evidence does not mention the use of Prila 5% cream in children, and the studies referenced are related to various other topics, including tuberculosis treatment, hidradenitis suppurativa management, and antifungal therapy. In the absence of specific guidance on the use of Prila 5% cream in children, it is prudent to exercise caution and avoid its use in this population to minimize potential risks and ensure the best possible outcomes in terms of morbidity, mortality, and quality of life 1.
From the FDA Drug Label
Pediatric Use: Controlled studies of lidocaine and prilocaine cream in children under the age of seven years have shown less overall benefit than in older children or adults. When using lidocaine and prilocaine cream in young children, especially infants under the age of 3 months, care must be taken to insure that the caregiver understands the need to limit the dose and area of application, and to prevent accidental ingestion. In neonates (minimum gestation age: 37 weeks) and children weighing less than 20 kg, the area and duration of application should be limited.
Prila 5% cream can be used in children, but with caution and careful consideration of the dose and area of application, especially in infants under 3 months. The caregiver should be informed of the need to limit the dose and prevent accidental ingestion. In children under 7 years, the cream has shown less overall benefit than in older children or adults 2.
From the Research
Prila 5% Cream Usage in Children
- There are no research papers to assist in answering this question, as the provided studies do not mention Prila 5% cream or its usage in children.
- The studies provided discuss various topics, including terbinafine's pharmacodynamic and pharmacokinetic properties 3, the use of lidocaine 2.5%/prilocaine 2.5% EMLA cream in children 4, terbinafine's broad spectrum of indications in several subcutaneous and systemic and parasitic diseases 5, the safety of tacrolimus 0.03% and 0.1% ointments in young children with atopic dermatitis 6, and terbinafine's activity against serious fungal pathogens 7.
- However, none of these studies mention Prila 5% cream or provide information on its usage in children.